Total trials
305
Active
72
Phase 3
34
Total enrollment
188,932
Pipeline matrix
Showing 32 of 32 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Phenoxymethylpenicillin | — | — | — | — | — | 1 | |
| PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity. | — | — | — | — | — | 1 | |
| Blood samples | — | — | — | — | 2 | ||
| Rituximab | — | — | — | — | — | 5 | |
| Prostaglandins | — | — | — | — | — | 1 | |
| Oxytocin | — | — | — | — | — | 1 | |
| Antihypertensive algorithm | — | — | — | — | — | 1 | |
| Standard of care | — | — | — | — | — | 1 | |
| Rabbit Anti thymocyte globulin | — | — | — | — | — | 1 | |
| Basiliximab | — | — | — | — | — | 1 | |
| Optimized and protocolized nebulization procedure. | — | — | — | — | — | 1 | |
| Experimental group: Patients will be treated with carvedilol. | — | — | — | — | — | 1 | |
| Dexmedetomidine | — | — | — | — | — | 1 | |
| Midazolam | — | — | — | — | — | 1 | |
| Avastin, 25 Mg/mL Intravenous Solution | — | — | — | — | — | 1 | |
| Nefopam | — | — | — | — | — | 1 | |
| NaCl 0.9% | — | — | — | — | — | 1 | |
| Furosemide 40 mg | — | — | — | — | — | 1 | |
| Rivaroxaban | — | — | — | — | — | 1 | |
| Propranolol, 120mg | — | — | — | — | — | 1 | |
| Caspofungin Acetate 50 MG | — | — | — | — | — | 1 | |
| Physiologic saline | — | — | — | — | — | 1 | |
| AAS at anti-inflammatory doses from 3 days to 14 days. | — | — | — | — | — | 1 | |
| Application of Diclofenac gel 1% twice a day | — | — | — | — | — | 1 | |
| Medical air | — | — | — | — | 3 | ||
| EMONO | — | — | — | — | 2 | ||
| Blood sample | — | — | — | — | — | 4 | |
| usual medical treatment | — | — | — | — | — | 1 | |
| HFNO weaning protocol | — | — | — | — | — | 1 | |
| HFNO Standard of care | — | — | — | — | — | 1 | |
| Injection of iohexol for glomerular filtration rate (GFR) measurement | — | — | — | — | — | 1 | |
| Samples | — | — | — | — | — | 1 |
Next readouts
- 2025-12
- 2026-04-03
- 2026-06
- 2026-07-16
- 2026-09
- 2026-09
- 2026-09-02
- 2027-01-30
- 2027-02
- 2027-07
Top conditions
- Amyotrophic Lateral Sclerosis7
- Breast Cancer6
- Rheumatoid Arthritis6
- Cystic Fibrosis5
- Alzheimer Disease5
- Autism Spectrum Disorder5
- Depression4
- Acute Respiratory Distress Syndrome3
Frequently asked questions about University Hospital, Tours
- How many clinical trials does University Hospital, Tours have on ClinicalTrials.gov?
- University Hospital, Tours is listed as the lead sponsor on 305 clinical trials in ClinicalTrials.gov, 72 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital, Tours's trials are in Phase 3?
- 34 of University Hospital, Tours's trials are in Phase 3, spread across 32 active drug programs.
- What therapeutic areas does University Hospital, Tours focus on?
- University Hospital, Tours's most-studied conditions on ClinicalTrials.gov are Amyotrophic Lateral Sclerosis, Breast Cancer, Rheumatoid Arthritis, Cystic Fibrosis, Alzheimer Disease.
- When are University Hospital, Tours's next clinical trial readouts?
- University Hospital, Tours has 10 upcoming primary-completion readouts tracked here; the soonest is “Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL)”, expected around 2025-12.